Abstract

Research Article

Anti COVID-19 immunity developed as assessed in a community-based oncological center

Benjamín Guix*, Teresa Guix, Marco Panichi, Ines Guix, Iván García, Carles Llebaría, Nicolás Achkar, Luis Quinzaños, Hamza Sentisi, Jose Luís Enríquez, Ana Galván, Cristina Pérez-Sánchez, Víctor González and Carmen León

Published: 07 October, 2020 | Volume 4 - Issue 1 | Pages: 038-041

Introduction: Serology (antibody) tests for the SARS-CoV-2 have been proposed as an instrument to inform health authorities about immunization during the COVID-19 pandemic. As there is a significant part of the population that may have some degree of immunity, it is of great interest to communicate the immunization results obtained in the first 500 healthcare workers (HCW), patients and relatives tested in a community-based Oncological Center.

Materials and methods: Between April 9th, 2020 and May 8th, 2020, a group of healthcare workers (HCW), their families, and general public who had had the COVID-19 or had been in close contact with confirmed cases of COVID-19 were screened for IgG SARS-CoV-2 antibodies. The tests were carried out in a rigorous manner, strictly following the guidelines approved by the Spanish Ministry of Health (Ministerio de Sanidad).

Results: The major objective of this study was to determine the proportion of asymptomatic infected individuals and those who had already secreted IgG against SARS-CoV-2 in our cancer treatment center or in the community of Barcelona. Patients were tested with PCR, Rapid diagnostic test (RDT) or enzyme-linked immunoabsorbent assay (ELISA). A total of 521 participants were tested, 206 with RDT and 315 with ELISA, 59 (11,32%) resulted positive to SARS-CoV-2.

Conclusion: RDT and ELISA proved to be effective and sensible enough to determine the extent of SARS-CoV-2 immunization in a community-based oncological center. The degree of immunization reached is nowadays far away from what can be considered desirable for a herd immunization.

Read Full Article HTML DOI: 10.29328/journal.acst.1001021 Cite this Article Read Full Article PDF

Keywords:

COVID-19; SARS-CoV-2; Seroprevalence; Antibody; PCR; RDT; ELISA; Immunity; Epidemiology; Health care workers; Barcelona; Spain

References

  1. Gronvall G, Connell N, Kobokobich A, et al. Developing a nacional strategy for serology (antobody testing) in the United States. Johns Hopkins, Bllomberg School of Public Health. Center for health security. www.centerforhealthsecurity.org
  2. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020; 25:2000180. PubMed: https://pubmed.ncbi.nlm.nih.gov/32183930/
  3. Whitehead S, Feibel C. CDC director on models for the months to come: ‘this virus is going to be with us.’ NPR.org March 31, 2020. https://www.npr.org/sections/health-shots/2020/03/31/824155179/cdc-director-on-models-for-the-months-to-come-this-virus-is-going-to-be-with-us
  4. Interpretación de las pruebas diagnósticas frente a SARS-CoV2. Version 2. Ministerio Sanidad. Instituto de Salud Carlos III. Gobierno de España, 2020.
  5. Resolución SLT/936/2020 de 4 de mayo, CVE-DOGC-B-20126004-2020.
  6. Recomendaciones para el manejo, prevención y control de COVID-19 en los ervicios de oncología radioterápica. Ministerio de Sanidad, Sociedad Española de Oncología Radioterápica. 2020.
  7. Kowk KO, Lai F, Wei W, Wong SYS, Tang JWT. Herdimmunity-estimating the level required to halt COVID-19 epidemies in affected countries. J Infect 2020; 80: e32-e33. PubMed: https://pubmed.ncbi.nlm.nih.gov/32209383/
  8. Estudio ENE-COVID19: Primera Ronda. Estudio nacional de sero-epidemiología de la infección por SARS-CoV-2 en España. Informe preliminar 13 de mayo de 2020. Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Consejo Interterritorial Sistema Nacional de Salud, Instituto de Salud Carlos III. 2020.
  9. Streeck H, Schulte B, Kümmerer B, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. www.ukbonn.de
  10. Lundkvist, A. Test provide new picture of the spread of the virus. Uppsala universitet. https://www.uu.se/en/news-media/news/article/?id=14756&typ=artikel
  11. Coronavirus (COVID-19) survey pilor: 2020 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/28may2020#measuring-the-data
  12. Garcia-Basteiro A, Moncunill G, Tortajada M, Vidal M, Guinovart C, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 11: 3500. PubMed: https://pubmed.ncbi.nlm.nih.gov/32641730/
  13. Folgueira MD, Muñoz-Ruipérez C, Alonso-López MA, P. Abascal L. SARS-CoV-2 infection in health care workers in a large public hospital in Madrid, Spain. J Hosp Infect. 2020; 106: 357–363. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371579/

Similar Articles

  • Anti COVID-19 immunity developed as assessed in a community-based oncological center
    Benjamín Guix*, Teresa Guix, Marco Panichi, Ines Guix, Iván García, Carles Llebaría, Nicolás Achkar, Luis Quinzaños, Hamza Sentisi, Jose Luís Enríquez, Ana Galván, Cristina Pérez-Sánchez, Víctor González and Carmen León Benjamín Guix*,Teresa Guix,Marco Panichi,Ines Guix,Iván García,Carles Llebaría,Nicolás Achkar,Luis Quinzaños,Hamza Sentisi,Jose Luís Enríquez,Ana Galván,Cristina Pérez-Sánchez,Víctor González,Carmen León. Anti COVID-19 immunity developed as assessed in a community-based oncological center. . 2020 doi: 10.29328/journal.acst.1001021; 4: 038-041

Recently Viewed

Read More

Most Viewed

Read More